Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Factors such growing treatment awareness and rising initiatives of government organizations in prevention of rabies are primarily driving the growth of human rabies treatment market globally.
The report titled Human rabies treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall human rabies treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on product type, treatment type and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global human rabies treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global human rabies treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global human rabies treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.
Rabies is a life-threatening viral disease that attacks the nervous system. It is usually spread to humans via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Human rabies treatment market is categorized on the basis of product type such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines and other. It is estimated that cell culture vaccines will show significant market growth during forecast period due to its safety, high immunogenicity, fewer adverse effects and negligible allergic reactions compared to other types of human rabies treatment. Human diploid cell strain vaccine (HDCV) is first cell culture vaccine but to overcome its higher cost, purified chicken embryo cell vaccine (PCECV) and purified vero cell culture rabies vaccine (PVRV) are available around the world by international pharmaceutical companies.
Rabies is a life-threatening illness spread via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Based treatment type, global rabies treatment market is segmented as pre-exposure immunization and post-exposure prophylaxis. It is estimated that pre-exposure immunization will show market growth during forecast period. As pre-exposure immunization is recommended for laboratory workers handling rabies and rabies related viruses, people whose activities might bring them into direct contact with animals and travelers to rabies-affected remote areas. It is studied that demand for post-exposure prophylaxis is increase in developing countries because post-exposure prophylaxis is the only safe and effective treatment available in market to prevent exposed persons from getting rabies. Post-exposure prophylaxis preferably involve management of animal bite wound, passive immunization and active immunization. According to world health organization (WHO), average cost of rabies post-exposure prophylaxis (PEP) is US$ 40 in Africa and US$ 49 in Asia. Every year, more than 15 million people worldwide receive a post-bite vaccination.
According to World health Organization (WHO), human rabies is present in 150 countries and territories and on all continents, except for Antarctica; and more than 10,000 people die each year from rabies. Globally, it is estimated that human mortality is highest in Asia, closely followed by Africa. According to Center for Disease Control and Prevention (CDC), human rabies is rare in United States with 1 to 3 cases reported annually. It is studied that, demand for pre-exposure immunization is highest in North America; United States is major regional market in North America. It is estimated that, Asia Pacific will show highest market growth during forecast period due to the increasing initiatives of government agencies and private organizations for prevention of rabies, populous countries, growing healthcare awareness and developing economic condition would expected to assist human rabies treatment market growth.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Human rabies treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall human rabies treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on product type, treatment type and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global human rabies treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global human rabies treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global human rabies treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.
Rabies is a life-threatening viral disease that attacks the nervous system. It is usually spread to humans via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Human rabies treatment market is categorized on the basis of product type such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines and other. It is estimated that cell culture vaccines will show significant market growth during forecast period due to its safety, high immunogenicity, fewer adverse effects and negligible allergic reactions compared to other types of human rabies treatment. Human diploid cell strain vaccine (HDCV) is first cell culture vaccine but to overcome its higher cost, purified chicken embryo cell vaccine (PCECV) and purified vero cell culture rabies vaccine (PVRV) are available around the world by international pharmaceutical companies.
Rabies is a life-threatening illness spread via the saliva of an infected animals. The rabies virus is generally transmitted through bites and scratches from infected animals. Based treatment type, global rabies treatment market is segmented as pre-exposure immunization and post-exposure prophylaxis. It is estimated that pre-exposure immunization will show market growth during forecast period. As pre-exposure immunization is recommended for laboratory workers handling rabies and rabies related viruses, people whose activities might bring them into direct contact with animals and travelers to rabies-affected remote areas. It is studied that demand for post-exposure prophylaxis is increase in developing countries because post-exposure prophylaxis is the only safe and effective treatment available in market to prevent exposed persons from getting rabies. Post-exposure prophylaxis preferably involve management of animal bite wound, passive immunization and active immunization. According to world health organization (WHO), average cost of rabies post-exposure prophylaxis (PEP) is US$ 40 in Africa and US$ 49 in Asia. Every year, more than 15 million people worldwide receive a post-bite vaccination.
According to World health Organization (WHO), human rabies is present in 150 countries and territories and on all continents, except for Antarctica; and more than 10,000 people die each year from rabies. Globally, it is estimated that human mortality is highest in Asia, closely followed by Africa. According to Center for Disease Control and Prevention (CDC), human rabies is rare in United States with 1 to 3 cases reported annually. It is studied that, demand for pre-exposure immunization is highest in North America; United States is major regional market in North America. It is estimated that, Asia Pacific will show highest market growth during forecast period due to the increasing initiatives of government agencies and private organizations for prevention of rabies, populous countries, growing healthcare awareness and developing economic condition would expected to assist human rabies treatment market growth.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Human Rabies Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Human Rabies Treatment market and their expected impact during the forecast period.
Market Segmentation
Product
- Cell Culture Vaccines
- Rabies Immunoglobulin
- Nerve Tissue Vaccines
- Others
Treatment
- Pre-Exposure Immunization
- Post-exposure prophylaxis
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Human Rabies Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Human Rabies Treatment market?
- Which is the largest regional market for Human Rabies Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Human Rabies Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Human Rabies Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Human Rabies Treatment Market
2.2. Global Human Rabies Treatment Market, By Product, 2021 (US$ Million)
2.3. Global Human Rabies Treatment Market, By Treatment, 2021 (US$ Million)
2.4. Global Human Rabies Treatment Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Human Rabies Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Human Rabies Treatment Market Vendors
3.2. Strategies Adopted by Human Rabies Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Human Rabies Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Human Rabies Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.2. Rabies Immunoglobulin
5.3.3. Nerve Tissue Vaccines
5.3.4. Others
6. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Pre-Exposure Immunization
6.3.2. Post-exposure prophylaxis
7. North America Human Rabies Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8. UK and European Union Human Rabies Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9. Asia Pacific Human Rabies Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10. Latin America Human Rabies Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11. Middle East and Africa Human Rabies Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
12. Company Profile
12.1. Bio Med Pvt. Ltd.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Biological E Ltd.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Cadila Healthcare
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. CSC Pharmaceuticals International
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. GlaxoSmithKline GmbH
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Grifols S.A.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Kamada Ltd.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Kedrion S.p.A.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Novartis International AG
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Sanofi Pasteur SA
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Serum institute of India
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Human Rabies Treatment Market
2.2. Global Human Rabies Treatment Market, By Product, 2021 (US$ Million)
2.3. Global Human Rabies Treatment Market, By Treatment, 2021 (US$ Million)
2.4. Global Human Rabies Treatment Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Human Rabies Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Human Rabies Treatment Market Vendors
3.2. Strategies Adopted by Human Rabies Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Human Rabies Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Human Rabies Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.2. Rabies Immunoglobulin
5.3.3. Nerve Tissue Vaccines
5.3.4. Others
6. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Pre-Exposure Immunization
6.3.2. Post-exposure prophylaxis
7. North America Human Rabies Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
7.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8. UK and European Union Human Rabies Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
8.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9. Asia Pacific Human Rabies Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.4.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.5.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
9.4.1.6.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10. Latin America Human Rabies Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
10.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11. Middle East and Africa Human Rabies Treatment Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.3. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.Human Rabies Treatment Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.1.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.2.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Human Rabies Treatment Market: By Product, 2020-2030, USD (Million)
11.4.1.3.1. Human Rabies Treatment Market: By Treatment, 2020-2030, USD (Million)
12. Company Profile
12.1. Bio Med Pvt. Ltd.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Biological E Ltd.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Cadila Healthcare
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. CSC Pharmaceuticals International
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. GlaxoSmithKline GmbH
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Grifols S.A.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Kamada Ltd.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Kedrion S.p.A.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Novartis International AG
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Sanofi Pasteur SA
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Serum institute of India
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Human Rabies Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Human Rabies Treatment Market: Quality Assurance
Figure 5 Global Human Rabies Treatment Market, By Product, 2021
Figure 6 Global Human Rabies Treatment Market, By Treatment, 2021
Figure 7 Global Human Rabies Treatment Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Human Rabies Treatment Market, 2021
Figure 9 Market Positioning of Key Human Rabies Treatment Market Players, 2021
Figure 10 Global Human Rabies Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Human Rabies Treatment Market, By Product, 2021 Vs 2030, %
Figure 12 Global Human Rabies Treatment Market, By Treatment, 2021 Vs 2030, %
Figure 13 U.S. Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 14 Canada Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 16 UK Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 17 Germany Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 18 Spain Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 19 Italy Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 20 France Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 22 China Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 23 Japan Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 24 India Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 25 Australia Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 26 South Korea Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 28 Brazil Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 29 Mexico Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 31 GCC Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 32 Africa Human Rabies Treatment Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Human Rabies Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 2 Global Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 3 North America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 4 North America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 5 U.S. Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 6 U.S. Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 7 Canada Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 8 Canada Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 9 Rest of North America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 10 Rest of North America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 11 UK and European Union Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 12 UK and European Union Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 13 UK Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 14 UK Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 15 Germany Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 16 Germany Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 17 Spain Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 18 Spain Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 19 Italy Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 20 Italy Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 21 France Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 22 France Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 23 Rest of Europe Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 24 Rest of Europe Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 25 Asia Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 26 Asia Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 27 China Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 28 China Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 29 Japan Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 30 Japan Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 31 India Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 32 India Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 33 Australia Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 34 Australia Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 35 South Korea Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 36 South Korea Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 37 Latin America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 38 Latin America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 39 Brazil Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 40 Brazil Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 41 Mexico Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 42 Mexico Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 43 Rest of Latin America Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 44 Rest of Latin America Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 45 Middle East and Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 46 Middle East and Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 47 GCC Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 48 GCC Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 49 Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 50 Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Human Rabies Treatment Market By Product, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Human Rabies Treatment Market By Treatment, 2020-2030, USD (Million)
Companies Mentioned
- Bio Med Pvt. Ltd.
- Biological E Ltd.
- Cadila Healthcare
- CSC Pharmaceuticals International
- GlaxoSmithKline GmbH
- Grifols S.A.
- Kamada Ltd.
- Kedrion S.p.A.
- Novartis International AG
- Sanofi Pasteur SA
- Serum institute of India
